Drug intelligence / Profile preview

allopurinol + ascorbic acid

Development stage: Preclinical
Lead developer: Ironwood Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

A combination of allopurinol, a xanthine oxidase inhibitor that reduces uric acid production, and ascorbic acid (vitamin C), an antioxidant vitamin. This combination has been studied for its effects on uric acid levels in gout patients and for potential cardiovascular benefits. Research indicates that while allopurinol effectively lowers uric acid levels, adding vitamin C provides only minimal additional urate-lowering effects in patients with established gout.

Other names: allopurinol + vitamin C

Targets

XO (Xanthine Oxidoreductase)

Beyond the preview

Go deeper on allopurinol + ascorbic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on allopurinol + ascorbic acid.

Explore the full profile